Clinical trial · Observational
A Real World Study of Anti-PD-1/PD-L1 Antibodies for the Treatment of Advanced Solid Tumors
NCT03787953CI-TRIAL-00038666unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study was designed to analyze the efficacy and safety of anti-PD-1/PD-L1 antibodies for the treatment of advanced solid tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Anti-PD-1/PD-L1 antibodies | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Anti-PD-1/PD-L1 antibodies
- description
- Patients with advanced solid tumors who visited Department of Medical Oncology, Chinese PLA General Hospital from 2015 to 2019 and received anti-PD-1/PD-L1 antibody therapy
- interventionNames
- Drug: Anti-PD-1/PD-L1 antibodies
Primary outcomes (1)
- measure
- Progression-free survival (PFS)
- timeFrame
- 6 months
- description
- PFS was defined as the length of time from the administration of the first-dose until disease progression or death from any cause before disease progression.
Secondary outcomes (4)
- measure
- Rate of adverse events (AEs)/ serious adverse events (SAEs) in patients with advanced solid tumors receiving anti-PD-1/PD-L1 antibody therapy.
- timeFrame
- up to 4 weeks after the last dose
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologically or cytologically confirmed advanced solid tumors; * Received anti-PD-1/PD-L1 antibody therapy. Exclusion Criteria: * No specific exclusion criteria in this real world study.
References
Publications (0)
Data not yet available
No reference posted for this study.